Pfizer Q3 revenue $16.58B beats $15.87B estimate

The guidance raise matters more than the top-line beat: lifting both revenue and adjusted EPS ranges signals management sees the strength as durable rather than a one-quarter timing effect. That said, the muted premarket move suggests expectations were already elevated, so the bar for a bigger re-rating was higher than a straightforward beat-and-raise. The open question is whether the upgraded outlook holds through the remainder of the year or proves conservative in hindsight.